Loading
A phase 1 trial of DAT-2645 run by Danatlas Pharmaceuticals Co., Ltd, not yet recruiting.
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway is a phase 1 interventional study registered as NCT06614751 by Danatlas Pharmaceuticals Co., Ltd, with 112 participants planned, started 2024-11-01. Conditions recorded: Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Endometrial Cancer, Gastric Cancer, Advanced Cancer and Metastatic Solid Tumors. Interventions recorded: DAT-2645 tablet and DAT-2645 tablet.
Shares DAT-2645, Danatlas Pharmaceuticals and the tag pipeline.
Shares Endometrial cancer, Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Danatlas Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Breast cancer (all types), Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Shares Breast cancer (all types), Metastatic cancer (cancer that has spread), Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/